BTIG initiated coverage of Oruka Therapeutics (ORKA) with a Buy rating and $44 price target The firm, which expects Oruka’s ORKA-001 and ORKA-002 monoclonal antibodies to thrive as monotherapies and also potentially in combination, sees “compelling reasons to believe” that ORKA-001 and ORKA-021 could eventually be confirmed with differentiated efficacy in the indications of psoriasis and psoriatic arthritis.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORKA:
- Buy Rating for Oruka Therapeutics: Promising Pipeline and Strong Financial Position
- Oruka Therapeutics: Strong Financial Position and Promising Clinical Developments Support Buy Rating
- Oruka Therapeutics reports Q1 EPS (40c), consensus (47c)
- Oruka Therapeutics’ ORKA-001: Promising Developments and Buy Rating Justification